Navigation Links
Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research
Date:9/14/2011

NEW YORK, Sept. 14, 2011 /PRNewswire/ -- Napoleone Ferrara, M.D., will receive the Johnson & Johnson Dr. Paul Janssen Award for Biomedical Research, including a $100,000 prize, this week during a series of events that celebrate his central role in the discovery of vascular endothelial growth factor (VEGF), the core signaling molecule of angiogenesis. His research has opened the door to the development of a new class of therapeutics to combat a serious eye disorder and contributed to the development of new oncology therapeutics. The Award aims to extend the legacy of Dr. Paul Janssen, an exceptionally gifted and passionate scientist who revolutionized modern medicine and inspired a new generation of researchers, by honoring the work of an active scientist in academia, industry or a scientific institute who has made a significant contribution to advancing human health.

(Photo:  http://photos.prnewswire.com/prnh/20110914/NY68250)

"Dr. Ferrara's groundbreaking research has made a direct impact on the quality of life of many thousands of people," said Paul Stoffels, M.D., Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. "We are pleased to recognize Dr. Ferrara's important achievements in advancing human well-being and his ongoing commitment to scientific innovation that embody the spirit of Dr. Paul Janssen."

Dr. Ferrara received recognition for this achievement at a reception last night and is also being honored during a scientific symposium today at the New York Academy of Sciences in New York. A formal award ceremony to honor Dr. Ferrara will also take place at the Dr. Paul Janssen Research Center in Beerse, Belgium tomorrow.

The symposium will feature presentations by Dr. Ferrara and other internationally renowned experts who have a seminal role in advancing anti-angiogenic therapies for ocular di
'/>"/>

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
2. Johnson & Johnson and Crucell Reach Agreement on Intended Public Offer of Euro 24.75 per Ordinary Share of Crucell
3. aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
4. Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
5. Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
6. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
7. Johnson & Johnson Completes Acquisition of Cougar Biotechnology
8. Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
9. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
10. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
11. Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... 16 Medical and technical experts at Wyle are ... Station. Their efforts will help astronauts cope with effects ... in a future mission to Mars. , "If successful, ... exploration missions and provide us with better insight into ...
... , , SEATTLE, Nov. 16 ... "Company") today announced that the Company,s product candidate PX-866, ... Information, Inc., as one of the Top 10 most ... partnering. , The selection was made by an independent ...
... , LONDON, Nov. 16 The ... field of biomarker research will test the frontiers of biomedical ... day and this rapid development promises excellent growth potential for ... in biomarker validation and assay development, there is a huge ...
Cached Biology Technology:Wyle Personnel Take Part in Important Studies Aboard the International Space Station 2Wyle Personnel Take Part in Important Studies Aboard the International Space Station 3Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover 2Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover 3Frost & Sullivan Reveals Strategies on Turning Challenges into Opportunities in the European Biomarkers Market 2
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/17/2014)... critical and pertinent for practicing physicians and clinicians given ... The Journal, Disaster Medicine and Public Health Preparedness ... Public Health, to surround the public, medical professionals and ... , On October 17, the journal published ... was prepared by Dr. Eric Toner, internist and emergency ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... few things as important on, and especially off, Earth as ... don,t have seconds to spare, which is why development of ... monitor can measure the concentrations of multiple gases within the ... designed the Multi-Gas Monitor to be resistant to shock and ...
... the right shape might be just as important in a ... an important role in the effectiveness of cells grown to ... design new structures that enable cells to "shape up," researchers ... come up with a way to measure, and more importantly, ...
... sound very durable. But the new type of micro-factories invented ... They will actually be placed inside a patient,s body ... will gradually dissolve and disappear in the patient,s urine once ... that Associate Professor of Chemistry Alexander Zelikin, Aarhus University, has ...
Cached Biology News:Rugged, rapid monitor safeguards space crews 2Rugged, rapid monitor safeguards space crews 3Shape-sifting: NIST categorizes bio scaffolds by characteristic cell shapes 2Tiny soft medicine factories 2
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
The Microseal 384 plate positioner ensures precise positioning of Microseal 384-well plates in the x-, y-, and z-dimensions, for accurate automated liquid handling....
... sealing material is suitable for PCR ... down heated lid), especially 384-well formats ... for sample retrieval. Multiple seals can ... Ideal for compound management and high ...
... Nikon's Digital Sight DS-U2 camera controller is ... is specifically designed to interface any of the ... a PC computer through a USB2.0 interface. The ... complicated and cumbersome installation by equipping both hub ...
Biology Products: